In addition, Vega et al. identified FMNL3 as a new RhoC-specific target, and showed that RhoC promotes polarized migration in PC3 prostate cancer and MDA-MB-231 breast cancer cells, respectively, through FMNL3. Here, RHOC is linked to prostate carcinoma.